MedTrace Logo

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

NCT00687271 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2019-01-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.

Conditions

Interventions

DRUG

MK-6213

MK-6213 160 mg for 4 weeks.

DRUG

Atorvastatin calcium

atorvastatin calcium 20mg for 4 weeks.

DRUG

Placebo for MK-6312 160 mg

DRUG

Placebo for Atorvastatin 20 mg

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-14
Primary Completion
2009-01-08
Completion
2009-01-08

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687271 on ClinicalTrials.gov